Cleveland Clinic trial shows gene-editing treatment can sharply lower cholesterol
A first-in-human clinical trial led by Cleveland Clinic is showing promising results for a new gene-editing treatment aimed at lowering cholesterol and triglycerides. Researchers tested an experimental CRISPR-Cas9 therapy called CTX310 in 15 patients with lipid disorders that were resistant to medication. The treatment is given as a one-time infusion Read more









